Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT04280276 · ClinicalTrials.gov registry record · NA
TruGraf Utilization in High IPV Levels
A NA study, sponsored by University of Maryland, Baltimore.
- Terminated
- Registry status
- NA
- Development phase
- 13
- Enrollment target
NCT04280276 is a NA study that was terminated before completion, run by University of Maryland, Baltimore. The registered enrollment target is 13 participants.
The verdict
NCT04280276, a NA study, was terminated before completion, sponsored by University of Maryland, Baltimore.
- TERMINATED
- Registry status
- NA
- Development phase
- 13 participants
- Enrollment target
Study Summary
Intra-patient variability (IPV) in tacrolimus is associated with premature graft loss. The rate of acute rejection episodes is higher in these patients, and acute rejection impacts negatively on graft survival. The prevalence of patients with high IPV is higher in African American patients (1-5). At the kidney transplant program of the University of Maryland, our investigators follow over 2.800 patients, with approximately 50% of the patients being of African American heritage, thus an ideal setting for the study.
Interventions
- DIAGNOSTIC_TEST TruGraf test
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 13 participants |
| Start Date | 2020-03-02 |
| Est. Completion | 2022-03-01 |
| Phase | NA |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT04280276
The ClinicalTrials.gov registry entry for NCT04280276 describes a study currently listed as terminated, categorized as NA. The registered enrollment target is 13 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is University of Maryland, Baltimore, which has 560 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which TruGraf test is the first listed.
NCT04280276 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT04280276 about?
NCT04280276 is a clinical study titled "TruGraf Utilization in High IPV Levels". Intra-patient variability (IPV) in tacrolimus is associated with premature graft loss. The rate of acute rejection episodes is higher in these patients, and acute rejection impacts negatively on graft survival. The prevalence of patients with high IPV is higher in African American patients (1-5). At...
What is the current status of trial NCT04280276?
This trial is currently terminated. It is a NA study. The enrollment target is 13 participants. The study started on 2020-03-02. Estimated completion is 2022-03-01.
What interventions are being tested in trial NCT04280276?
The interventions under investigation include: TruGraf test (DIAGNOSTIC_TEST).
Who is sponsoring clinical trial NCT04280276?
This trial is sponsored by University of Maryland, Baltimore, which has 560 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.